ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2479

REMS technology 5-y Imminent Fracture Risk in Systemic Sclerosis.

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2043

Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2381

Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2507

Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)

(2504–2523) Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2468

RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2480

Respiratory Muscle Weakness in a Systemic Sclerosis Cohort

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2098

Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1854

Resting-State Functional Magnetic Resonance Imaging Analysis Revealed Altered Functional Connectivity Associated with Fatigue in Systemic Lupus Erythematosus

(1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2072

Results of an Integrated Program for Early Cancer Detection in Idiopathic Inflammatory Myopathies

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1954

Revolutionizing Microvascular Screening: AI-Powered Dermatoscopy for Efficient Nailfold Capillary Evaluation

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2182

Rheum for Improvement: A Needs Assessment Survey for an Internal Medicine Resident Curriculum

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 2150

Rheum to Grow:An Approach Towards Human Centered Design through a Qualitative Analysis on the Transition from Pediatric to Adult Rheumatology

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2167

Rheum4Games: A Game-Based Rheumatology Board Review for Internal Medicine Residents

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1880

Rheumatoid Arthritis Mortality in the U.S. (1999–2020): A Decline in Rates, But Not in Disparities

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2149

Rheumatology Transitions of Care: Patient Stability and Follow-Up at a Single Center

(2124–2158) Pediatric Rheumatology – Clinical Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].